Descripción del proyecto
Un armazón de menisco innovador contra la artrosis
Las meniscectomías a menudo conducen a una artrosis temprana, que requiere estrategias reconstructivas alternativas. El proyecto MEFISTO, financiado con fondos europeos, propone desarrollar un armazón funcionalizado basado en nanomateriales capaz de interactuar con el tejido meniscal previo. Este innovador dispositivo promoverá la revascularización local y ayudará a regenerar el menisco nativo, especialmente en pacientes más jóvenes. En paralelo administrará fármacos de forma local para modular la inflamación tisular en pacientes con artrosis avanzada. Dada la gran cantidad de personas que se somete a meniscectomías, las intervenciones de MEFISTO mejorarán los resultados de la cirugía y reducirán las comorbilidades relacionadas con la artrosis.
Objetivo
MEFISTO will develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy knee osteoarthritis (OA) in Europe. Morphological profiling will identify the population of patients who, after meniscal resection, are at higher risk of early compartment degeneration, providing a personalized approach for the patient. The two different reconstructive strategies are: i) a controlled vascularized bioactive biodegradable meniscal scaffold, which will regenerate the native meniscus. This strategy will address younger patients with early osteoarthritic changes. ii) a bioactive non-biodegradable meniscal prosthesis, which will act as a mechanical unloading device and a drug delivery system, with the capacity to modulate the inflammatory environment. This strategy will address patients with advanced OA. A socio-economic analysis of the efficacy of existing meniscal substitutes will complete the project. This analysis is of vital importance for the European healthcare system, as it will provide a clear understanding of the costs and benefits of current clinical practice and predict the impact of the two new interventions. The technological innovation lies in the development of biologically active functionalized nanobiomaterials that can interact with the surrounding articular tissues. The biodegradable scaffold will promote revascularization in the peripheral zone, while leaving the inner zone avascular, reflecting the native meniscal tissue and functionalization with drug delivery micro/nanoparticles of the non-biodegradable device will provide modulation of inflammation. The impact is expected to be significant as so many patients have undergone or will undergo meniscectomy. The interventions developed in MEFISTO will prevent these patients from receiving joint-sacrificing procedures such as metal prosthesis whilst reducing the social burden, associated costs and high levels of morbidity resulting from OA.
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-NMBP-TR-IND-2018
Régimen de financiación
RIA - Research and Innovation actionCoordinador
76534 Baden-Baden
Alemania